CA2199002C - Micropores sur la peau humaine pour l'administration de medicaments et suivi medical - Google Patents
Micropores sur la peau humaine pour l'administration de medicaments et suivi medicalInfo
- Publication number
- CA2199002C CA2199002C CA002199002A CA2199002A CA2199002C CA 2199002 C CA2199002 C CA 2199002C CA 002199002 A CA002199002 A CA 002199002A CA 2199002 A CA2199002 A CA 2199002A CA 2199002 C CA2199002 C CA 2199002C
- Authority
- CA
- Canada
- Prior art keywords
- tlle
- selected area
- stratum corneum
- skin
- light source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000012544 monitoring process Methods 0.000 title claims description 19
- 238000012377 drug delivery Methods 0.000 title description 6
- 210000003491 skin Anatomy 0.000 claims abstract description 204
- 238000000034 method Methods 0.000 claims abstract description 148
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 145
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000000126 substance Substances 0.000 claims abstract description 53
- 239000012491 analyte Substances 0.000 claims abstract description 48
- 239000003623 enhancer Substances 0.000 claims abstract description 18
- 230000035699 permeability Effects 0.000 claims abstract description 18
- 238000010521 absorption reaction Methods 0.000 claims abstract description 15
- 238000010438 heat treatment Methods 0.000 claims abstract description 15
- 230000002708 enhancing effect Effects 0.000 claims abstract description 10
- 210000001519 tissue Anatomy 0.000 claims description 115
- 239000000523 sample Substances 0.000 claims description 91
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 90
- 239000008103 glucose Substances 0.000 claims description 90
- 230000004907 flux Effects 0.000 claims description 41
- 239000007787 solid Substances 0.000 claims description 40
- 210000002615 epidermis Anatomy 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000001816 cooling Methods 0.000 claims description 21
- 230000003287 optical effect Effects 0.000 claims description 19
- 238000009834 vaporization Methods 0.000 claims description 18
- 230000008016 vaporization Effects 0.000 claims description 18
- 230000004888 barrier function Effects 0.000 claims description 17
- 230000035807 sensation Effects 0.000 claims description 17
- 210000003722 extracellular fluid Anatomy 0.000 claims description 16
- 230000005284 excitation Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- XEGGRYVFLWGFHI-UHFFFAOYSA-N bendiocarb Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)O2 XEGGRYVFLWGFHI-UHFFFAOYSA-N 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 238000007398 colorimetric assay Methods 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 41
- 239000003814 drug Substances 0.000 abstract description 41
- 239000012530 fluid Substances 0.000 abstract description 29
- 238000002679 ablation Methods 0.000 abstract description 28
- 230000005611 electricity Effects 0.000 abstract description 3
- 239000012141 concentrate Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000003628 erosive effect Effects 0.000 abstract 1
- 239000000975 dye Substances 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 60
- 239000008280 blood Substances 0.000 description 53
- 210000004369 blood Anatomy 0.000 description 53
- 239000010410 layer Substances 0.000 description 51
- 230000006378 damage Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 230000008569 process Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 14
- 239000011148 porous material Substances 0.000 description 14
- 210000004207 dermis Anatomy 0.000 description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 12
- 229910052802 copper Inorganic materials 0.000 description 12
- 239000010949 copper Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000000699 topical effect Effects 0.000 description 12
- 238000004088 simulation Methods 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960004194 lidocaine Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000037317 transdermal delivery Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 229910002056 binary alloy Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- -1 aqueous emlllsiolls Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000005476 soldering Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000007514 turning Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101100396735 Mus musculus Il36a gene Proteins 0.000 description 2
- YFONKFDEZLYQDH-OPQQBVKSSA-N N-[(1R,2S)-2,6-dimethyindan-1-yl]-6-[(1R)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine Chemical compound C[C@@H](F)C1=NC(N)=NC(N[C@H]2C3=CC(C)=CC=C3C[C@@H]2C)=N1 YFONKFDEZLYQDH-OPQQBVKSSA-N 0.000 description 2
- 241001307210 Pene Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101100203319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) skh1 gene Proteins 0.000 description 2
- 235000014328 Schoenoplectus acutus var occidentalis Nutrition 0.000 description 2
- 244000136421 Scirpus acutus Species 0.000 description 2
- 235000014326 Scirpus californicus Nutrition 0.000 description 2
- 235000017913 Scirpus lacustris Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UFYXKDMLGBKHIC-UHFFFAOYSA-N 3-(4-hydroxy-2-phenylphenanthren-3-yl)-2-phenylphenanthren-4-ol Chemical compound C=1C2=CC=C3C=CC=CC3=C2C(O)=C(C=2C(=CC3=C(C4=CC=CC=C4C=C3)C=2O)C=2C=CC=CC=2)C=1C1=CC=CC=C1 UFYXKDMLGBKHIC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000270650 Alytes Species 0.000 description 1
- 241001006782 Amage Species 0.000 description 1
- 101100113576 Arabidopsis thaliana CINV2 gene Proteins 0.000 description 1
- 101001057426 Archaeoglobus fulgidus (strain ATCC 49558 / DSM 4304 / JCM 9628 / NBRC 100126 / VC-16) Iron-sulfur flavoprotein AF_1896 Proteins 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- MWRWFPQBGSZWNV-UHFFFAOYSA-N Dinitrosopentamethylenetetramine Chemical compound C1N2CN(N=O)CN1CN(N=O)C2 MWRWFPQBGSZWNV-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241001435619 Lile Species 0.000 description 1
- 241000935673 Liodes Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940075911 depen Drugs 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- HJXPPCPJEYUQFQ-HNNXBMFYSA-N dodecyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H]1CCC(=O)N1 HJXPPCPJEYUQFQ-HNNXBMFYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000002305 electric material Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012904 visual particle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
- A61B2017/00172—Pulse trains, bursts, intermittent continuous operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00761—Removing layer of skin tissue, e.g. wrinkles, scars or cancerous tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00765—Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Laser Surgery Devices (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Méthode pour rendre la peau plus perméable à un analyte aux fins du diagnostic ou à un médicament à des fins thérapeutiques, qui fait appel à une technique de perçage d'un micropore et, facultativement, à l'énergie sonique et à un activateur chimique. Si l'on a recours à l'énergie sonique, celle-ci peut être modulée de différentes façons : modulation de fréquence, modulation d'amplitude, modulation de phase ou combinaisons de types de modulation. Pour percer un micropore, a) on enlève la couche cornée en chauffant rapidement en un point l'eau de façon à vaporiser l'eau et à éroder ainsi les cellules; b) on perfore la couche cornée avec une micro-lancette calibrée de façon à pratiquer un micropore pouvant atteindre environ 1 000 m de diamètre; c) on enlève la couche cornée en concentrant un faisceau bien focalisé d'énergie sonique sur la couche cornée; d) on perfore hydrauliquement la couche cornée avec un jet ou un liquide à haute pression pour former un micropore pouvant atteindre environ 1 000 m de diamètre, ou e) on perfore la couche cornée avec de brèves impulsions d'énergie électrique pour former un micropore pouvant atteindre environ 1 000 m de diamètre. Un colorant avec un maximum d'absorption correspondant à la longueur d'onde d'une source de lumière pulsée peut être absorbée dans la couche cornée pour concentrer l'énergie de la source de lumière pulsée et faciliter l'ablation de la couche cornée. Ou encore on peut mettre la couche cornée en contact avec un fil sous tension.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52054795A | 1995-08-29 | 1995-08-29 | |
| US08/520,547 | 1995-08-29 | ||
| US804395P | 1995-10-30 | 1995-10-30 | |
| US60/008,043 | 1995-10-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2199002A1 CA2199002A1 (fr) | 1997-03-01 |
| CA2199002C true CA2199002C (fr) | 1999-02-23 |
Family
ID=26677684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002199002A Expired - Lifetime CA2199002C (fr) | 1995-08-29 | 1996-08-29 | Micropores sur la peau humaine pour l'administration de medicaments et suivi medical |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0858285A4 (fr) |
| JP (2) | JP3899427B2 (fr) |
| CN (1) | CN1174713C (fr) |
| AU (1) | AU707065B2 (fr) |
| BR (1) | BR9610012A (fr) |
| CA (1) | CA2199002C (fr) |
| ES (1) | ES2536459T3 (fr) |
| GB (1) | GB2307414B (fr) |
| HK (1) | HK1009321A1 (fr) |
| IL (1) | IL123379A (fr) |
| NO (1) | NO334437B1 (fr) |
| PT (1) | PT1563788E (fr) |
| TR (1) | TR199800347T1 (fr) |
| WO (1) | WO1997007734A1 (fr) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251100B1 (en) | 1993-09-24 | 2001-06-26 | Transmedica International, Inc. | Laser assisted topical anesthetic permeation |
| ATE234129T1 (de) | 1996-06-18 | 2003-03-15 | Alza Corp | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
| ATE241405T1 (de) * | 1996-07-03 | 2003-06-15 | Altea Therapeutics Corp | Mehrfache mechanische mikroperforierung von haut oder schleimhäuten |
| ATE231015T1 (de) * | 1996-09-17 | 2003-02-15 | Deka Products Lp | System zur medikamentenabgabe durch transport |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US6527716B1 (en) | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
| ATE365026T1 (de) * | 1996-12-31 | 2007-07-15 | Altea Therapeutics Corp | Mikroporation von gewebe zur verabreichung von bioaktiven substanzen |
| US6027496A (en) * | 1997-03-25 | 2000-02-22 | Abbott Laboratories | Removal of stratum corneum by means of light |
| JP4338307B2 (ja) | 1997-10-21 | 2009-10-07 | アボット・ラボラトリーズ | 間質液を収集する装置および方法 |
| US6155992A (en) * | 1997-12-02 | 2000-12-05 | Abbott Laboratories | Method and apparatus for obtaining interstitial fluid for diagnostic tests |
| US6918901B1 (en) | 1997-12-10 | 2005-07-19 | Felix Theeuwes | Device and method for enhancing transdermal agent flux |
| EP1037686B1 (fr) * | 1997-12-11 | 2005-08-17 | Alza Corporation | Dispositif renfor ant le flux d'agents transdermiques |
| WO1999029364A1 (fr) * | 1997-12-11 | 1999-06-17 | Alza Corporation | Dispositif renforçant le flux d'agents transdermiques |
| DE69839969D1 (de) | 1997-12-11 | 2008-10-16 | Alza Corp | Vorrichtung zur verbesserung des transdermalen flusses von medikamenten |
| ATE375752T1 (de) * | 1998-03-06 | 2007-11-15 | Spectrx Inc | Integrierte gewebeporations-, flüssigkeitsammel- und analysevorrichtung |
| US6530915B1 (en) | 1998-03-06 | 2003-03-11 | Spectrx, Inc. | Photothermal structure for biomedical applications, and method therefor |
| US6173202B1 (en) * | 1998-03-06 | 2001-01-09 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| US6091975A (en) * | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| US6569157B1 (en) * | 1998-05-18 | 2003-05-27 | Abbott Laboratories | Removal of stratum corneum by means of light |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US7344499B1 (en) | 1998-06-10 | 2008-03-18 | Georgia Tech Research Corporation | Microneedle device for extraction and sensing of bodily fluids |
| US6077660A (en) * | 1998-06-10 | 2000-06-20 | Abbott Laboratories | Diagnostic assay requiring a small sample of biological fluid |
| DK1124607T3 (da) | 1998-07-14 | 2009-01-26 | Altea Therapeutics Corp | Kontrolleret fjernelse af biologisk membran ved hjælp af pyroteknisk ladning til transmembran transport |
| MXPA01000698A (es) * | 1998-07-21 | 2002-04-08 | Spectrx Inc | Sistema y metodo para el monitoreo de analito continuo. |
| US7384396B2 (en) | 1998-07-21 | 2008-06-10 | Spectrx Inc. | System and method for continuous analyte monitoring |
| DE69906992T2 (de) * | 1998-09-04 | 2004-02-05 | Powderject Research Ltd. | Zweite medizinische indikation einer partikelverabreichungsmethode |
| US6468229B1 (en) | 1998-10-20 | 2002-10-22 | Abbott Laboratories | Apparatus and method for the collection of interstitial fluids |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
| US6597946B2 (en) | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
| US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| CN100402105C (zh) * | 1999-06-08 | 2008-07-16 | 奥尔蒂治疗学公司 | 采用薄膜组织界面装置在生物膜中制作微孔的设备及方法 |
| US20030078499A1 (en) | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
| US6355054B1 (en) * | 1999-11-05 | 2002-03-12 | Ceramoptec Industries, Inc. | Laser system for improved transbarrier therapeutic radiation delivery |
| DE19963034A1 (de) | 1999-12-24 | 2001-06-28 | Roche Diagnostics Gmbh | System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit |
| IL136008A0 (en) | 2000-05-07 | 2001-05-20 | Elecsys Ltd | Electrically-mediated transdermal drug injection |
| US6706032B2 (en) | 2000-06-08 | 2004-03-16 | Massachusetts Institute Of Technology | Localized molecular and ionic transport to and from tissues |
| US7597692B2 (en) | 2000-06-08 | 2009-10-06 | Massachusetts Institute Of Technology | Microscission processes and procedures |
| AUPR044000A0 (en) * | 2000-09-28 | 2000-10-26 | Norwood Abbey Ltd | Diagnostic device |
| US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
| US6882884B1 (en) | 2000-10-13 | 2005-04-19 | Soundskin, L.L.C. | Process for the stimulation of production of extracellular dermal proteins in human tissue |
| US6733493B2 (en) * | 2000-11-16 | 2004-05-11 | Innotech Usa, Inc. | Laser skin perforator |
| EP1345646A2 (fr) | 2000-12-14 | 2003-09-24 | Georgia Tech Research Corporation | Appareils a microaiguilles et fabrication |
| US7027478B2 (en) | 2000-12-21 | 2006-04-11 | Biovalve Technologies, Inc. | Microneedle array systems |
| JP2005504002A (ja) | 2001-02-13 | 2005-02-10 | ガバメント オブ ザ ユナイテッド ステイツ、 アズ リプリゼンティッド バイ ザ セクレタリィ オブ ジ アーミイ | 経皮免疫感作のためのワクチン |
| JP4704583B2 (ja) * | 2001-02-28 | 2011-06-15 | 有限会社開発顧問室 | パッチテスト用シート |
| US6790179B2 (en) | 2001-08-01 | 2004-09-14 | Johnson & Johnson Consumer Companies, Inc. | Method of examining and diagnosing skin health |
| US6840910B2 (en) | 2001-08-01 | 2005-01-11 | Johnson & Johnson Consumer Companies, Inc. | Method of distributing skin care products |
| US6855117B2 (en) | 2001-08-01 | 2005-02-15 | Johnson & Johnson Consumer Companies, Inc. | Method of treating the skin of a subject |
| US8361037B2 (en) | 2001-09-19 | 2013-01-29 | Valeritas, Inc. | Microneedles, microneedle arrays, and systems and methods relating to same |
| EP1471953B1 (fr) | 2001-09-21 | 2011-02-16 | Valeritas, Inc. | Amenagements de micro-aiguilles activees par pression de gaz, systemes et procedes correspondants |
| EP2319577B1 (fr) | 2001-11-07 | 2017-03-15 | Syneron Medical Ltd. | Système intégré d'administration transdermale de médicaments |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| AU2003225735A1 (en) | 2002-03-11 | 2003-09-29 | Altea Therapeutics Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
| AU2003226605A1 (en) | 2002-04-19 | 2003-11-03 | Transpharma Medical Ltd. | Handheld transdermal drug delivery and analyte extraction |
| US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| IL152573A (en) | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
| IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
| US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
| US20050089554A1 (en) * | 2003-10-24 | 2005-04-28 | Cormier Michel J. | Apparatus and method for enhancing transdermal drug delivery |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| AU2004285484A1 (en) * | 2003-10-24 | 2005-05-12 | Alza Corporation | Pretreatment method and system for enhancing transdermal drug delivery |
| US7896819B2 (en) | 2004-10-21 | 2011-03-01 | Rebec Mihailo V | Method of determining the concentration of an analyte in a body fluid and system in therefor |
| JP2006326147A (ja) * | 2005-05-30 | 2006-12-07 | Shingo Wakamatsu | レーザー治療装置 |
| TWI419717B (zh) * | 2005-06-17 | 2013-12-21 | Altea Therapeutics Corp | 滲透傳送系統及其使用方法 |
| JP5011936B2 (ja) * | 2006-10-11 | 2012-08-29 | パナソニック株式会社 | 血液検査装置 |
| JP5011935B2 (ja) * | 2006-10-11 | 2012-08-29 | パナソニック株式会社 | 血液検査装置 |
| KR101214764B1 (ko) * | 2006-11-14 | 2012-12-21 | 가고시마 유니버시티 | 약물주입장치 |
| RU2328739C1 (ru) * | 2007-02-26 | 2008-07-10 | Айрат Анварович Халиков | Способ определения целостности клеточных мембран биологической ткани трупа |
| BRPI0810969A2 (pt) | 2007-04-27 | 2015-01-27 | Echo Therapeutics Inc | Dispositivo de permeação da pele para a detecção de analito ou liberação transdermal de fármaco |
| WO2016141136A1 (fr) * | 2015-03-03 | 2016-09-09 | Guided Therapy Systems, Llc | Procédés et systèmes pour l'administration assistée par ultrasons d'un médicament dans un tissu |
| WO2009047774A2 (fr) | 2007-10-09 | 2009-04-16 | Transpharma Ltd. | Fixation magnétique d'un timbre transdermique |
| US8281675B2 (en) | 2007-10-17 | 2012-10-09 | Syneron Medical Ltd | Dissolution rate verification |
| JP5407868B2 (ja) * | 2007-11-06 | 2014-02-05 | コニカミノルタ株式会社 | 微小開口形成装置およびそれを用いる体液収集システム |
| KR101464058B1 (ko) | 2007-12-05 | 2014-11-20 | 시네론 메디컬 리미티드 | 일회용 전자기 에너지 애플리케이터 및 그 사용방법 |
| GB0811856D0 (en) | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
| US8606366B2 (en) | 2009-02-18 | 2013-12-10 | Syneron Medical Ltd. | Skin treatment apparatus for personal use and method for using same |
| US20100256466A1 (en) * | 2009-04-02 | 2010-10-07 | Avraham Shekalim | Metabolite Management System |
| US9402678B2 (en) | 2009-07-27 | 2016-08-02 | Novoxel Ltd. | Methods and devices for tissue ablation |
| PT105635B (pt) | 2011-04-19 | 2014-04-11 | Univ De Coimbra | Dispositivo para a administração eficiente de compostos na pele ou barreiras biológicas, ou através dessas, usando filmes finos absorventes de luz |
| PL3082634T3 (pl) | 2013-12-18 | 2021-10-18 | Novoxel Ltd. | Urządzenie do odparowywania tkanek |
| WO2016042546A2 (fr) | 2014-09-15 | 2016-03-24 | Novoxel Ltd. | Procédés et dispositifs pour la vaporisation et la compression thermiques de tissu |
| EP3193758A1 (fr) * | 2014-09-15 | 2017-07-26 | Novoxel Ltd. | Procédés et dispositifs pour la vaporisation et l'incision de tissus par chirurgie thermique |
| WO2017102867A1 (fr) * | 2015-12-15 | 2017-06-22 | Koninklijke Philips N.V. | Dispositif et procédé de traitement de surface |
| EP3403092A4 (fr) * | 2016-01-15 | 2019-08-28 | University of Cincinnati | Dispositifs et procédés d'électroporation avancés pour accès d'analyte dans des biofluides |
| CN109640858B (zh) * | 2016-06-20 | 2022-02-01 | 北德克萨斯大学 | 非整体复合骨材料的激光辅助加工(lam) |
| FI127811B (en) * | 2016-11-21 | 2019-03-15 | Helsingin Yliopisto | Device for sampling one or more analytes |
| EP3361402B1 (fr) * | 2017-02-14 | 2024-12-04 | Roche Diabetes Care GmbH | Une méthode mise en oeuvre par ordinateur et un dispositif portable pour analyser les données de surveillance du glucose indicatives d'un taux de glucose dans un liquide corporel, et un support non transitoire lisible par odinateur |
| US11441994B2 (en) * | 2017-07-27 | 2022-09-13 | Tata Consultancy Services Limited | Method and system for in-silico design of skin electroporation |
| US20210129136A1 (en) * | 2017-08-03 | 2021-05-06 | Fibrotx Oü | Lateral flow assay and device for skin care application |
| CN109157280A (zh) * | 2018-08-10 | 2019-01-08 | 重庆大学 | 不可逆电穿孔组织消融效果动态实时评估设备 |
| DK3804648T3 (da) * | 2018-08-23 | 2022-04-11 | Novocure Gmbh | Anvendelse af elektriske vekseltrømsfelter til forøgelse af permeabilitet af blodhjernebarrieren |
| EP3990063A4 (fr) * | 2019-06-28 | 2023-07-05 | PassPort Technologies, Inc. | Procédés et systèmes de commande de la distribution d'énergie à des dispositifs à filament |
| CN119097308A (zh) * | 2019-08-02 | 2024-12-10 | 华广生技股份有限公司 | 生理讯号传感装置 |
| CN110613893A (zh) * | 2019-10-31 | 2019-12-27 | 南京工业职业技术学院 | 一种新型励磁线圈 |
| CN111693434B (zh) * | 2020-06-19 | 2024-01-19 | 中建路桥集团有限公司 | 一种测试混凝土抗渗性能的实验装置 |
| CN114504373A (zh) * | 2020-11-16 | 2022-05-17 | 澳美力科技(成都)有限公司 | 一种新型射频变频美容仪 |
| CN112957124B (zh) * | 2021-01-30 | 2023-08-22 | 南京理工大学 | 一种能量靶向调控的离体激光生物组织焊接缝合方法 |
| CN113397698B (zh) * | 2021-05-20 | 2023-04-18 | 东莞市飞越激光设备有限公司 | 一种保证高精度和高速度的激光切线装置 |
| CN114343839B (zh) * | 2021-12-30 | 2024-07-23 | 德州环球之光医疗科技股份有限公司 | 一种基于可调的螺旋线型激光光斑的治疗图形转换方法 |
| CN116999687B (zh) * | 2023-07-19 | 2024-11-12 | 河南翔宇医疗设备股份有限公司 | 一种超声渗透仪以及超声渗透仪输出参数设置装置、介质 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775361A (en) * | 1986-04-10 | 1988-10-04 | The General Hospital Corporation | Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| JP2798459B2 (ja) * | 1988-01-21 | 1998-09-17 | マサチユセツツ・インスチチユート・オブ・テクノロジー | エレクトロポレーションを利用した診断装置及び分子の組織内移動装置 |
| US5139023A (en) * | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
| US5016615A (en) * | 1990-02-20 | 1991-05-21 | Riverside Research Institute | Local application of medication with ultrasound |
| US5115805A (en) * | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
| GB9014307D0 (en) * | 1990-06-27 | 1990-08-15 | Scient Generics Ltd | Method of treatment and compositions therefor |
| JP3189337B2 (ja) * | 1991-11-08 | 2001-07-16 | 日本電気株式会社 | 皮膚角層の除去器具および除去方法 |
| US5344418A (en) * | 1991-12-12 | 1994-09-06 | Shahriar Ghaffari | Optical system for treatment of vascular lesions |
| US5165418B1 (en) | 1992-03-02 | 1999-12-14 | Nikola I Tankovich | Blood sampling device and method using a laser |
| US5246437A (en) * | 1992-04-10 | 1993-09-21 | Abela George S | Cell treatment apparatus and method |
| US5643252A (en) * | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| US5279552A (en) * | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
| US5267985A (en) * | 1993-02-11 | 1993-12-07 | Trancell, Inc. | Drug delivery by multiple frequency phonophoresis |
| US5582184A (en) * | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
| US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
| US5445611A (en) | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
| DE69624668T2 (de) * | 1995-07-25 | 2003-08-28 | Massachusetts Institute Of Technology, Cambridge | Verbesserter transdermaler transport unter verwendung von ultraschall |
-
1996
- 1996-08-29 CN CNB961966718A patent/CN1174713C/zh not_active Expired - Lifetime
- 1996-08-29 CA CA002199002A patent/CA2199002C/fr not_active Expired - Lifetime
- 1996-08-29 EP EP96929098A patent/EP0858285A4/fr not_active Withdrawn
- 1996-08-29 GB GB9702766A patent/GB2307414B/en not_active Expired - Lifetime
- 1996-08-29 JP JP51055297A patent/JP3899427B2/ja not_active Expired - Lifetime
- 1996-08-29 TR TR1998/00347T patent/TR199800347T1/xx unknown
- 1996-08-29 BR BR9610012-5A patent/BR9610012A/pt not_active Application Discontinuation
- 1996-08-29 AU AU68631/96A patent/AU707065B2/en not_active Expired
- 1996-08-29 IL IL12337996A patent/IL123379A/en not_active IP Right Cessation
- 1996-08-29 WO PCT/US1996/013865 patent/WO1997007734A1/fr not_active Ceased
- 1996-08-29 ES ES05011002.2T patent/ES2536459T3/es not_active Expired - Lifetime
- 1996-08-29 HK HK98110113A patent/HK1009321A1/xx not_active IP Right Cessation
- 1996-08-29 PT PT50110022T patent/PT1563788E/pt unknown
-
1998
- 1998-02-27 NO NO19980878A patent/NO334437B1/no not_active IP Right Cessation
-
2006
- 2006-02-15 JP JP2006038655A patent/JP2006192285A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NO980878L (no) | 1998-04-27 |
| WO1997007734A1 (fr) | 1997-03-06 |
| AU6863196A (en) | 1997-03-19 |
| EP0858285A1 (fr) | 1998-08-19 |
| ES2536459T3 (es) | 2015-05-25 |
| GB9702766D0 (en) | 1997-04-02 |
| JP2006192285A (ja) | 2006-07-27 |
| IL123379A0 (en) | 1998-09-24 |
| GB2307414B (en) | 1998-03-11 |
| AU707065B2 (en) | 1999-07-01 |
| PT1563788E (pt) | 2015-06-02 |
| BR9610012A (pt) | 1999-12-21 |
| CA2199002A1 (fr) | 1997-03-01 |
| JPH11511360A (ja) | 1999-10-05 |
| NO980878D0 (no) | 1998-02-27 |
| TR199800347T1 (xx) | 1998-05-21 |
| JP3899427B2 (ja) | 2007-03-28 |
| CN1195276A (zh) | 1998-10-07 |
| EP0858285A4 (fr) | 2000-05-17 |
| CN1174713C (zh) | 2004-11-10 |
| IL123379A (en) | 2002-04-21 |
| NO334437B1 (no) | 2014-03-03 |
| HK1009321A1 (en) | 1999-05-28 |
| GB2307414A (en) | 1997-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2199002C (fr) | Micropores sur la peau humaine pour l'administration de medicaments et suivi medical | |
| US5885211A (en) | Microporation of human skin for monitoring the concentration of an analyte | |
| CA2789115C (fr) | Formation de micropores sur un tissu pour l'administration d'agents bioactifs | |
| US9579380B2 (en) | Microporation of tissue for delivery of bioactive agents | |
| US6527716B1 (en) | Microporation of tissue for delivery of bioactive agents | |
| US20020169394A1 (en) | Integrated tissue poration, fluid harvesting and analysis device, and method therefor | |
| US5458140A (en) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers | |
| EP1059939B1 (fr) | Appareil permettant d'accroitre les debits d'un fluide dans un tissu biologique rendu microporeux | |
| AU738597B2 (en) | Laser assisted topical anesthetic permeation | |
| US5445611A (en) | Enhancement of transdermal delivery with ultrasound and chemical enhancers | |
| Lee et al. | Permeabilization and recovery of the stratum corneum in vivo: the synergy of photomechanical waves and sodium lauryl sulfate | |
| EP1563788B1 (fr) | Microporation de la peau humaine pour l'administration des médicaments et applications de surveillance | |
| RU2209031C2 (ru) | Формирование микропор в коже человека для доставки лекарственных препаратов и мониторинга | |
| WO2002026148A1 (fr) | Permeation et prelevement ameliores par irradiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160829 |